Jun 09, 2020
Soligenix to Present at the MedInvest Infectious Disease and Immunology Investor Conference
Dec 12, 2019
Soligenix Initiates Clinical Trial of its Heat Stable Ricin Toxin Vaccine
Nov 18, 2019
Soligenix to Present at the PCG Spotlight Series Conference
Sep 12, 2019
GT Biopharma Announces FDA Notification of Commencement of Enrollment in Human GTB-3550 Trike(TM) Phase i/ii Clinical Trial
Jun 13, 2019
Soligenix to Present RiVax® Program at the 13 Annual CounterACT Network Research Symposium
Feb 11, 2019
Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®
Nov 12, 2018
Soligenix Selected to Present RiVax® Data at the Fourth International Conference on Vaccines Research & Development in Baltimore, Maryland
Oct 30, 2018
G3 Pharmaceuticals Signs Exclusive License and Option Agreement for Treating Diastolic Heart Failure (HFpEF) by Inhibiting Galectin-3.
Oct 03, 2018
Arrest after suspicious packages sent to Pentagon: media
Oct 03, 2018
Pentagon says castor seeds, not ricin, in suspect packages
Oct 03, 2018
Pentagon packages test positive for substance close to ricin
Oct 03, 2018
Ricin suspected in mail sent to Trump, Pentagon
Oct 02, 2018
Parcels sent to Pentagon suspected to contain ricin: official
Aug 03, 2018
Data Projects the NASH Market Will Eclipse USD 21 Billion by 2025
Jul 09, 2018
Soligenix Receives European and Canadian Patents for its Ricin Toxin Vaccine (RiVax®) Formulation
Jun 15, 2018
European Hematology Association: First-in-Human CLL1-CD33 Compound CAR T Cells as a Two-Pronged Approach for the Treatment of Refractory Acute Myeloid Leukemia
Mar 22, 2018
Soligenix Receives Orphan Drug Designation from the European Commission for RiVax® for Prevention of Ricin Poisoning
Nov 27, 2017
Soligenix Announces Presentation and Poster at the 2017 Chemical and Biological Defense Science and Technology Conference in Long Beach, CA
Sep 14, 2017
G3 Pharmaceuticals to Pursue a Novel Class of Cardiovascular Pharmaceuticals